Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective: Amyloid‐β(Aβ) aggregates are presumed to be found in the brain at an early stage of Alzheimer's disease (AD) but have seldom been assessed by brain biopsy during life in often elderly patients. Methods: Between 1991 and 2006 we evaluated 468 patients with suspected normal pressure hydrocephalus with intraventricular pressure monitoring and a right frontal cortical biopsy sample immunostained for Aβ and hyperphosphorylated tau (HPτ). Adequate samples and the clinical follow‐up data until death or the end of 2008, available in 433 cases, were reviewed for the clinical signs of dementia, including AD. Logistic regression analysis was used to analyze whether Aβ and/or HPτ in the biopsy samples obtained during life predicted development of cognitive impairment, in particular, AD. Results: Of the 433 frontal cortical samples, 42 (10%) displayed both Aβ and HPτ, 144 (33%) Aβ only, and 247 (57%) neither Aβ nor HPτ. In a median follow‐up time of 4.4 years, 94 patients (22%) developed clinical AD. The presence of both Aβ and HPτ was strongly associated (odds ratio [OR], 68.2; 95% confidence interval [CI], 22.1–210) and Aβ alone significantly associated (OR, 10.8; 95% CI, 4.9–23.8) with the clinical diagnosis of AD. Interpretation: This is the largest follow‐up study of patients assessed for the presence of Aβ and HPτ in frontal cortical brain biopsy samples. 1) The presence of Aβ and HPτ spoke strongly for the presence or later development of clinical AD; 2) Aβ alone was suggestive of AD; and 3) the absence of Aβ and HPτ spoke against a later clinical diagnosis of AD. Ann Neurol 2010;68:446–453
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 2×
“Currently, a neuropathological assessment of the brain at autopsy is the only method available to confirm Ab and HPs deposits and reach the definite diagnosis of AD.(2,3) Ab aggregation is first noted in the cerebral cortex(3) and HPs is first seen in the olfactory bulb and hippocampal formation.”
BackgroundBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“Accumulation of amyloid-b(Ab) and hyperphosphorylated tau (HPs) in the brain, in predetermined neuroanatomical regions, are considered diagnostic hallmarks of Alzheimer’s disease (AD).(1,2) Currently, a neuropathological assessment of the brain at autopsy is the only method available to confirm Ab and HPs deposits and…”
BackgroundSelf-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Self-citationMultimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 4×
“Clinical dementia of AD is usually preceded by deterioration of episodic memory, and a correct diagnosis at the mild cognitive impairment (prodromal AD) phase would lengthen the window for potential mechanism-based interventions to inhibit AD pathogenesis.(8) The accumulation of Ab is thought to appear years before th…”
BackgroundInfluentialEarly Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationAlzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response
Golomb, J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.778 · Cited by 279
Leinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199 · cited 3×
“presence of Ab aggregates in the frontal cortical biopsy correlated well with the PIB uptake in PET.(16) It is obvious, however, that the biopsy site in the right frontal cortex does not always reflect the actual Ab load due to the rather patchy depositions of Ab in the brain, ie, a negative biopsy does not definitely…”
BackgroundInfluentialSelf-citation
Cited by
Depression and risk of developing dementia
Byers, A. L., & Yaffe, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.60 · Cited by 1,265
Normal aging induces A1-like astrocyte reactivity
Clarke, L. E., Liddelow, S. A., Chakraborty, C., Münch, A. E., Heiman, M., & Barres, B. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800165115 · Cited by 1,237
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
“In our opinion, autopsy and brain banks will become more important, rather than less important, in the future, as new biomarkers will continue to require autopsy validation, as has been done for amyloid imaging agents,(96,342) although it is possible that brain biopsy may also help meet this need.(343,344) Due to the…”
BackgroundGlymphatic System Impairment in Alzheimer’s Disease and Idiopathic Normal Pressure Hydrocephalus
Reeves, B. C., Karimy, J. K., Kundishora, A. J., Mestre, H., Cerci, H. M., Matouk, C., Alper, S. L., Lundgaard, I., Nedergaard, M., & Kahle, K. T. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.11.008 · Cited by 403
Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.03.006 · Cited by 332
Metadata
- Authors
- Leinonen, V., Koivisto, A. M., Savolainen, S., Rummukainen, J., Tamminen, J. N., Tillgren, T., Vainikka, S., Pyykkö, O. T., Mölsä, J., Fraunberg, M., Pirttilä, T., Jääskeläinen, J. E., Soininen, H., Rinne, J., & Alafuzoff, I.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-10
- Volume
- 68
- Issue
- 4
- Pages
- 446-453
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2097870720
- Cited by
- 150
- References
- 15
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.